{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T10:40:17Z","timestamp":1736937617912,"version":"3.33.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,6]],"date-time":"2024-10-06T00:00:00Z","timestamp":1728172800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.ad.2024.10.017","type":"journal-article","created":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T00:03:38Z","timestamp":1728605018000},"page":"T81-T86","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["[Translated article] Avelumab to treat Merkel cell carcinoma: real-life experience in a dedicated oncology center"],"prefix":"10.1016","volume":"116","author":[{"given":"E.","family":"R\u00edos-Vi\u00f1uela","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Garc\u00eda-V\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.J.","family":"Juan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Nagore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Requena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Sanmart\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Llombart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ad.2024.10.017_bib0125","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/cup.13910","article-title":"Merkel cell carcinoma: A review","volume":"48","author":"Walsh","year":"2021","journal-title":"J Cutan Pathol."},{"key":"10.1016\/j.ad.2024.10.017_bib0130","doi-asserted-by":"crossref","first-page":"17077","DOI":"10.1038\/nrdp.2017.77","article-title":"Merkel cell carcinoma","volume":"3","author":"Becker","year":"2017","journal-title":"Nat Rev Dis Primers."},{"key":"10.1016\/j.ad.2024.10.017_bib0135","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.ad.2015.12.008","article-title":"Cancer Incidence and Mortality in Spain: A Systematic Review and Meta-Analysis","volume":"107","author":"Tejera-Vaquerizo","year":"2016","journal-title":"Actas Dermosifiliogr."},{"key":"10.1016\/j.ad.2024.10.017_bib0140","doi-asserted-by":"crossref","first-page":"e002646","DOI":"10.1136\/jitc-2021-002646","article-title":"First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study","volume":"9","author":"D\u2019Angelo","year":"2021","journal-title":"J Immunother Cancer."},{"key":"10.1016\/j.ad.2024.10.017_bib0145","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/S1470-2045(16)30364-3","article-title":"Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial","volume":"17","author":"Kaufman","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ad.2024.10.017_bib0150","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ejca.2022.03.043","article-title":"Diagnosis and treatment of Merkel cell carcinoma: European consensus-based interdisciplinary guideline - Update 2022","volume":"171","author":"Gauci","year":"2022","journal-title":"Eur J Cancer."},{"key":"10.1016\/j.ad.2024.10.017_bib0155","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jaad.2021.04.024","article-title":"Clinical impact of immunotherapy in Merkel cell carcinoma patients: A systematic review and meta-analysis","volume":"87","author":"Garza-Davila","year":"2022","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.ad.2024.10.017_bib0160","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.jaad.2016.05.045","article-title":"A high neutrophil-to-lymphocyte ratio as a potential marker of mortality in patients with Merkel cell carcinoma: A retrospective study","volume":"75","author":"Zaragoza","year":"2016","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.ad.2024.10.017_bib0165","doi-asserted-by":"crossref","first-page":"e002478","DOI":"10.1136\/jitc-2021-002478","article-title":"Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma","volume":"9","author":"Nghiem","year":"2021","journal-title":"J Immunother Cancer."},{"key":"10.1016\/j.ad.2024.10.017_bib0170","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s00262-017-2092-x","article-title":"Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibody","volume":"67","author":"Suh","year":"2018","journal-title":"Cancer Immunol Immunother."},{"key":"10.1016\/j.ad.2024.10.017_bib0175","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.jaad.2017.12.004","article-title":"Merkel cell carcinoma: An update and review: Current and future therapy","volume":"78","author":"Tello","year":"2018","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.ad.2024.10.017_bib0180","doi-asserted-by":"crossref","first-page":"102081","DOI":"10.1016\/j.canep.2021.102081","article-title":"Clinical and pathological features of Merkel cell carcinoma: A 4-year follow-up observational retrospective study in Spain","volume":"76","author":"R\u00edos-Mart\u00edn","year":"2022","journal-title":"Cancer Epidemiol."},{"key":"10.1016\/j.ad.2024.10.017_bib0185","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.2217\/fon-2017-0072","article-title":"Systematic literature review of efficacy, safety and tolerability outcomes of chemotherapy regimens in patients with metastatic Merkel cell carcinoma","volume":"13","author":"Nghiem","year":"2017","journal-title":"Future Oncol."},{"key":"10.1016\/j.ad.2024.10.017_bib0190","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40425-017-0310-x","article-title":"Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after \u2265 1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial","volume":"6","author":"Kaufman","year":"2018","journal-title":"J Immunother Cancer."},{"key":"10.1016\/j.ad.2024.10.017_bib0195","doi-asserted-by":"crossref","first-page":"e180077","DOI":"10.1001\/jamaoncol.2018.0077","article-title":"Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma: A Preplanned Interim Analysis of a Clinical Trial","volume":"4","author":"D\u2019Angelo","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ad.2024.10.017_bib0200","doi-asserted-by":"crossref","first-page":"e000313","DOI":"10.1136\/jitc-2019-000313","article-title":"Efficacy and safety of avelumab treatment in patients with metastatic Merkel cell carcinoma: experience from a global expanded access program","volume":"8","author":"Walker","year":"2020","journal-title":"J Immunother Cancer."},{"key":"10.1016\/j.ad.2024.10.017_bib0205","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.2217\/fon-2020-1250","article-title":"Real-world clinical outcomes with first-line avelumab in locally advanced\/metastatic Merkel cell carcinoma in the USA: SPEAR-Merkel","volume":"17","author":"Cowey","year":"2021","journal-title":"Future Oncol."},{"key":"10.1016\/j.ad.2024.10.017_bib0210","doi-asserted-by":"crossref","first-page":"e001076","DOI":"10.1136\/jitc-2020-001076","article-title":"Avelumab for advanced Merkel cell carcinoma in the Netherlands: a real-world cohort","volume":"8","author":"Levy","year":"2020","journal-title":"J Immunother Cancer."},{"key":"10.1016\/j.ad.2024.10.017_bib0215","doi-asserted-by":"crossref","first-page":"12065","DOI":"10.1002\/cam4.5890","article-title":"Avelumab for the treatment of locally advanced or metastatic Merkel cell carcinoma-A multicenter real-world experience in Israel","volume":"12","author":"Averbuch","year":"2023","journal-title":"Cancer Med."},{"key":"10.1016\/j.ad.2024.10.017_bib0220","doi-asserted-by":"crossref","first-page":"e1633","DOI":"10.1002\/onco.13845","article-title":"Real-World Clinical Outcomes in Patients with Locally Advanced or Metastatic Merkel Cell Carcinoma Treated in U.S. Oncology Clinical Practices: Results from SPEAR-Merkel","volume":"26","author":"Bhanegaonkar","year":"2021","journal-title":"Oncologist."},{"key":"10.1016\/j.ad.2024.10.017_bib0225","doi-asserted-by":"crossref","first-page":"e004904","DOI":"10.1136\/jitc-2022-004904","article-title":"Real-world clinical outcomes with avelumab in patients with Merkel cell carcinoma treated in the USA: a multicenter chart review study","volume":"10","author":"Bhatia","year":"2022","journal-title":"J Immunother Cancer."},{"key":"10.1016\/j.ad.2024.10.017_bib0230","doi-asserted-by":"crossref","first-page":"e003198","DOI":"10.1136\/jitc-2021-003198","article-title":"Clinical and molecular characteristics associated with response to therapeutic PD-1\/PD-L1 inhibition in advanced Merkel cell carcinoma","volume":"10","author":"Spassova","year":"2022","journal-title":"J Immunother Cancer."},{"key":"10.1016\/j.ad.2024.10.017_bib0235","doi-asserted-by":"crossref","first-page":"1141500","DOI":"10.3389\/fonc.2023.1141500","article-title":"Body mass index and baseline platelet count as predictive factors in Merkel cell carcinoma patients treated with avelumab","volume":"13","author":"Incorvaia","year":"2023","journal-title":"Front Oncol."},{"key":"10.1016\/j.ad.2024.10.017_bib0240","doi-asserted-by":"crossref","first-page":"5084","DOI":"10.3390\/cancers15205084","article-title":"An Updated Review of the Biomarkers of Response to Immune Checkpoint Inhibitors in Merkel Cell Carcinoma: Merkel Cell Carcinoma and Immunotherapy","volume":"15","author":"Fojnica","year":"2023","journal-title":"Cancers (Basel)."}],"container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731024007749?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731024007749?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T08:57:49Z","timestamp":1736845069000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001731024007749"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S0001731024007749"],"URL":"https:\/\/doi.org\/10.1016\/j.ad.2024.10.017","relation":{},"ISSN":["0001-7310"],"issn-type":[{"type":"print","value":"0001-7310"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"[Translated article] Avelumab to treat Merkel cell carcinoma: real-life experience in a dedicated oncology center","name":"articletitle","label":"Article Title"},{"value":"Actas Dermo-Sifiliogr\u00e1ficas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2024.10.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2024.01.023","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Espa\u00f1a, S.L.U. on behalf of AEDV.","name":"copyright","label":"Copyright"}]}}